Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes - PubMed (original) (raw)

Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes

M Laakso et al. Diabetologia. 1987 Sep.

Abstract

We measured serum lipids, lipoproteins and post-heparin plasma lipases, lipoprotein lipase and hepatic lipase, in 12 female patients with Type 1 (insulin-dependent) diabetes (postglucagon C-peptide undetectable), in 11 female insulin-treated patients with Type 2 (non-insulin-dependent) diabetes (postglucagon C-peptide greater than 0.60 nmol/l) and in 16 non-diabetic female control subjects. These three groups of subjects were similar with respect to age and obesity. Insulin dose was similar in patients with Type 1 and with Type 2 diabetes. HDL and HDL2 cholesterol were lower in patients with Type 2 diabetes than in non-diabetic control subjects (p less than 0.05) but did not differ between patients with Type 1 diabetes and non-diabetic control subjects. No difference in lipoprotein lipase activity was seen between the groups. The highest levels of lipoprotein lipase and hepatic lipase activities were observed in patients with Type 2 diabetes. Lipoprotein lipase activity correlated significantly with HDL cholesterol in patients with Type 1 diabetes (p less than 0.01) and in patients with Type 2 diabetes (p less than 0.001) but not in control subjects. Hepatic lipase activity did not correlate significantly with HDL cholesterol in any of the groups. In conclusion, postheparin plasma lipoprotein lipase and hepatic lipase activities do not seem to explain the difference in HDL cholesterol concentration between patients with Type 1 and Type 2 diabetes.

PubMed Disclaimer

Similar articles

• Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism.
  Nikkilä EA, Huttunen JK, Ehnholm C. Nikkilä EA, et al. Diabetes. 1977 Jan;26(1):11-21. doi: 10.2337/diab.26.1.11. Diabetes. 1977. PMID: 187516
• High-density lipoprotein cholesterol concentrations and postheparin hepatic and lipoprotein lipases in obesity: relationships with plasma insulin levels.
  Cominacini L, Garbin U, Davoli A, Campagnola M, De Santis A, Pasini C, Pastorino AM, Bosello O. Cominacini L, et al. Ann Nutr Metab. 1993;37(4):175-84. doi: 10.1159/000177766. Ann Nutr Metab. 1993. PMID: 8215234
• The effects of gender and type of diabetes on HDL-cholesterol.
  Merrin PK, Baynes C, Henderson A, Richmond B, Elkeles R. Merrin PK, et al. Diabete Metab. 1994 Jan-Feb;20(1):20-4. Diabete Metab. 1994. PMID: 8056130
• Reduced HDL2 cholesterol subspecies and elevated postheparin hepatic lipase activity in older men with abdominal obesity and asymptomatic myocardial ischemia.
  Katzel LI, Coon PJ, Busby MJ, Gottlieb SO, Krauss RM, Goldberg AP. Katzel LI, et al. Arterioscler Thromb. 1992 Jul;12(7):814-23. doi: 10.1161/01.atv.12.7.814. Arterioscler Thromb. 1992. PMID: 1616906

Cited by

• Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
  Hirano T, Hayashi T, Sugita H, Tamasawa A, Goto S, Tomoyasu M, Yamamoto T, Ohara M, Terasaki M, Kushima H, Ito Y, Yamagishi SI, Mori Y. Hirano T, et al. J Diabetes Investig. 2023 Dec;14(12):1401-1411. doi: 10.1111/jdi.14076. Epub 2023 Aug 30. J Diabetes Investig. 2023. PMID: 37647503 Free PMC article. Clinical Trial.
• Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol.
  Hirano T, Kodera R, Hirashima T, Suzuki N, Aoki E, Hosoya M, Oshima T, Hayashi T, Koba S, Ohta M, Satoh N, Ito Y. Hirano T, et al. J Atheroscler Thromb. 2022 May 1;29(5):762-774. doi: 10.5551/jat.62789. Epub 2021 Apr 29. J Atheroscler Thromb. 2022. PMID: 33952832 Free PMC article.
• The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo.
  Schiekofer S, Kleber ME, Maerz W, Rasche FM, Schneider JG. Schiekofer S, et al. Int J Endocrinol. 2017;2017:2869090. doi: 10.1155/2017/2869090. Epub 2017 May 30. Int J Endocrinol. 2017. PMID: 28638407 Free PMC article.
• Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
  Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR. Hiukka A, et al. Diabetologia. 2007 Oct;50(10):2067-75. doi: 10.1007/s00125-007-0751-8. Epub 2007 Jul 26. Diabetologia. 2007. PMID: 17653691 Clinical Trial.
• Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.
  Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS. Ebara T, et al. J Clin Invest. 2000 Jun;105(12):1807-18. doi: 10.1172/JCI8283. J Clin Invest. 2000. PMID: 10862796 Free PMC article.

References

1. 1. Annu Rev Med. 1980;31:97-108 - PubMed
2. 1. J Clin Invest. 1982 Oct;70(4):791-7 - PubMed
3. 1. Diabetes. 1981 Feb;30(2):132-8 - PubMed
4. 1. Clin Chim Acta. 1975 Sep 16;63(3):335-47 - PubMed
5. 1. N Engl J Med. 1984 Oct 11;311(15):953-9 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information